Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
Spending More for Lung Cancer Treatment Did Not Substantially Increase Patients' Lives
A new study finds that survival for elderly patients with lung cancer has changed little despite large increases in health-care expenditures for lung cancer treatment. The study by Harvard University, National Cancer Institute, and National Bureau of Economic Research researchers, to be published in the December 1, 2007, issue of Cancer, finds that average life expectancy rose by less than 1 month between 1983 and 1997, while costs rose by over $20,000 per patient.
Stable 5-Year Survival Rate
Lung cancer remains the top cause of cancer death in the United States, with an estimated 160,390 deaths expected to occur in 2007. The US spends more than $5
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
